Literature DB >> 15919899

The C terminus of the B5 receptor for herpes simplex virus contains a functional region important for infection.

Pilar Perez-Romero1, A Oveta Fuller.   

Abstract

The expression of a previously uncharacterized human hfl-B5 cDNA confers susceptibility for herpes simplex virus (HSV) to porcine cells and fulfills criteria as an HSV entry receptor (A. Perez, Q.-X. Li, P. Perez-Romero, G. DeLassus, S. R. Lopez, S. Sutter, N. McLaren, and A. Oveta Fuller, J. Virol. 79:7419-7430, 2005). Heptad repeats found in the B5 C terminus are predicted to form an alpha-helix for coiled coil structure. We used mutagenesis and synthetic peptides with wild-type and mutant sequences to examine the function of the heptad repeat motif in HSV binding and entry into porcine cells that express B5 and for infection of naturally susceptible human HEp-2 cells. B5 with point mutations predicted to disrupt the putative C-terminal coiled coil failed to mediate HSV binding and entry into porcine cells. Synthetic peptides that contain the single amino acid changes lose the blocking activity of HSV entry. We concluded that the C terminus of B5 contains a functional region that is important for the B5 receptor to mediate events in HSV entry. Structural evidence that this functional region forms coiled coil structures is under investigation. Blocking of HSV interaction with the C-terminal region of the B5 receptor is a new potential target site to intervene in the virus infection of human cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919899      PMCID: PMC1143627          DOI: 10.1128/JVI.79.12.7431-7437.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection.

Authors:  Q Yao; R W Compans
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

2.  Coiled-coil domains in proteins secreted by type III secretion systems.

Authors:  M J Pallen; G Dougan; G Frankel
Journal:  Mol Microbiol       Date:  1997-07       Impact factor: 3.501

3.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Phosphatidylinositol-dependent membrane fusion induced by a putative fusogenic sequence of Ebola virus.

Authors:  M B Ruiz-Argüello; F M Goñi; F B Pereira; J L Nieva
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Authors:  L T Rimsky; D C Shugars; T J Matthews
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

Authors:  D M Lambert; S Barney; A L Lambert; K Guthrie; R Medinas; D E Davis; T Bucy; J Erickson; G Merutka; S R Petteway
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.

Authors:  J K Judice; J Y Tom; W Huang; T Wrin; J Vennari; C J Petropoulos; R S McDowell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion.

Authors:  D Navarro; P Paz; L Pereira
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

9.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

10.  Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers.

Authors:  T Danieli; S L Pelletier; Y I Henis; J M White
Journal:  J Cell Biol       Date:  1996-05       Impact factor: 10.539

View more
  7 in total

1.  A new class of receptor for herpes simplex virus has heptad repeat motifs that are common to membrane fusion proteins.

Authors:  Aleida Perez; Qing-Xue Li; Pilar Perez-Romero; Gregory Delassus; Santiago R Lopez; Sarah Sutter; Ning McLaren; A Oveta Fuller
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 2.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

3.  Formation and reversible dissociation of coiled coil of peptide to the C-terminus of the HSV B5 protein: a time-resolved spectroscopic analysis.

Authors:  Ordel J Brown; Santiago A Lopez; A Oveta Fuller; Theodore Goodson
Journal:  Biophys J       Date:  2007-05-11       Impact factor: 4.033

4.  Triggering and visualizing the aggregation and fusion of lipid membranes in microfluidic chambers.

Authors:  Daniel J Estes; Santiago R Lopez; A Oveta Fuller; Michael Mayer
Journal:  Biophys J       Date:  2006-04-14       Impact factor: 4.033

5.  HSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target.

Authors:  Natalia Cheshenko; Janie B Trepanier; Theodore J Segarra; A Oveta Fuller; Betsy C Herold
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

6.  Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.

Authors:  Radeekorn Akkarawongsa; Nina E Pocaro; Gary Case; Aaron W Kolb; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

7.  Therapeutic approaches using host defence peptides to tackle herpes virus infections.

Authors:  Håvard Jenssen
Journal:  Viruses       Date:  2009-11-18       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.